Articles tagged with Lung Cancer
The Phase 1CA240-0007 trial demonstrates a 29% overall response rate and 80% disease control rate for BMS-986504 in heavily pretreated patients with MTAP-deleted NSCLC. The agent selectively targets the PRMT5-MTA complex while sparing normal tissue.
The Phase 2 IDeate-Lung01 trial demonstrated a confirmed objective response rate of 48.2% and disease control rate of 87.6% in patients with recurrent or progressive ES-SCLC. Ifinatamab deruxtecan showed manageable safety and high response rates, supporting further investigation in small cell lung cancer.
A Phase 3 trial found that crizotinib did not prolong disease-free survival in patients with resected early-stage ALK+ NSCLC. The study included 166 patients and followed them for a median of 58.3 months.
The global Phase 3 HARMONi trial found that ivonescimab plus chemotherapy significantly prolonged progression-free survival (PFS) in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations. Median PFS was 6.8 months, and the overall response rate was higher in the ivonescimab group.
A Phase 1 study of SHR-4849 demonstrated early signs of anti-tumor activity in patients with relapsed small cell lung cancer, with an objective response rate of 59.5% and disease control rate of 90.5%. The drug showed manageable safety and favorable pharmacokinetics.
Zidesamtinib demonstrated clinically meaningful activity and durability in patients with ROS1-positive NSCLC who had progressed on prior TKI therapy. Durable responses were observed in patients with CNS involvement, ROS1 G2032R mutations, and multiple prior ROS1 TKIs.
The ACROSS 2 Phase III trial demonstrates that combining aumolertinib with platinum-pemetrexed chemotherapy significantly improves progression-free survival in patients with advanced/metastatic NSCLC harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations. The treatment regimen showed a manageable safety pr...
The FLAURA2 trial shows osimertinib plus chemotherapy significantly improves overall survival compared to osimertinib monotherapy in patients with EGFR-mutated advanced NSCLC. The combination also demonstrates a manageable safety profile, extending survival for these patients.
The COMPEL trial demonstrates that patients with EGFR-mutated advanced non-small cell lung cancer benefit from continued osimertinib treatment in combination with platinum-based chemotherapy. This approach is associated with improved progression-free survival and overall survival compared to placebo plus chemotherapy.
A novel antibody-drug conjugate iza-bren demonstrated an objective response rate of 66.0% and a confirmed ORR of 56.0% in EGFR-mutated NSCLC patients, with manageable safety profile. The median progression-free survival was 12.5 months.
The CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life in patients with resectable non-small cell lung cancer, including those with Stage III N2 disease. Nivolumab also reduces risk of symptom deterioration in these high-risk patients.
A combination of iza-bren and osimertinib demonstrated a 100% objective response rate in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer. The regimen was also manageable from a safety perspective, with most treatment-related adverse events being hematologic.
A new study validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population. The model demonstrated high predictive accuracy for lung cancer risk up to six years after a single low-dose CT scan.
The ASTRO's 2025 Annual Meeting will feature pivotal studies in radiation medicine, highlighting advances in radiopharmaceutical therapy and new indications for low-dose radiation therapy. The meeting will also explore cutting-edge techniques for prostate, breast, lung, and other common cancers.
Researchers found a new variant of mesothelioma associated with inherited germline BAP1 mutations, which are less aggressive and may respond to therapy. These patients also develop multiple tumors and require early cancer detection screening.
Lung cancer subtypes differ in metabolic profiles, with metabolomics offering insights into subtype-specific alterations. Metabolomics enables effective subtype differentiation and identification of potential biomarkers for early diagnosis and personalized therapy.
A new guideline from the Canadian Task Force on Preventive Health Care provides a menu of effective options to help people quit smoking, including behavioural and medication options. The guideline aims to address the challenges of nicotine addiction and offers personalized choices for quitting tobacco.
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
Scientists have developed a monoclonal antibody to combat life-threatening inflammatory diseases like sepsis and ARDS. The antibody shows promise in blocking the immune system's hyperactive response and restoring healthy function without unwanted side effects.
A new web-based tool has been developed to provide tailored resources for states and local leaders to reduce lung cancer mortality rates. The tool addresses health equity and incorporates user feedback to offer recommendations based on regional needs.
A new multi-institutional study confirmed that the NSD2 protein can be targeted with a new drug, blocking it effectively reprogrammed DNA structure, reversed and prevented cancer growth in preclinical models of KRAS-mutant lung and pancreatic cancers. Targeting the brain-liver pathway with electronic wearables could prevent cancer-asso...
The symposium will feature talks by leading researchers on various aspects of cancer, including molecular discovery, clinical application, and population impact. Key findings include the exploration of genomic inequities and their impact on cancer disparities.
A new study in The American Journal of Pathology reveals that perilipin 2 protein modulates aggressive cancer progression in advanced lung adenocarcinoma by regulating lipid droplet accumulation. High perilipin 2 expression is associated with more aggressive disease progression and shorter recurrence-free survival times.
Researchers have developed a novel technology that can simultaneously silence two notoriously difficult-to-target cancer-related genes, KRAS and MYC. This innovation has the potential to treat cancers that have been challenging to treat, with significant implications for patients.
The study aims to create a path forward for improved treatment, access to clinical trials, and personalized care for communities with limited access to care. Recent studies highlight the need to address systemic barriers that prevent many people from receiving advanced care.
A higher intake of ultra-processed food is linked to an increased risk of lung cancer. Limiting UPF consumption may help reduce the global burden of the disease. Research found that participants in the highest quarter of energy-adjusted UPF consumption were 41% more likely to be diagnosed with lung cancer.
The American College of Chest Physicians has released a clinical guideline on the management of patients with early-stage non-small cell lung cancer. The guideline provides evidence-based recommendations for primary treatment and outlines three flowchart graphs outlining the recommended course of treatment based on patient risk. These ...
Researchers at Chongqing Medical University discovered NF-kappa-B-activating protein-like (NKAPL) acts as a tumor suppressor in non-small cell lung cancer by stabilizing TRIM21 and inhibiting NF-κB signaling. Restoration of NKAPL expression suppresses cancer progression, offering new diagnostic and therapeutic strategies.
Researchers have discovered a promising new approach to suppress the growth of aggressive cancers by targeting minor splicing, a specialized molecular process. By blocking minor splicing, cancer cells accumulate DNA damage and trigger cell death, while healthy cells remain largely unaffected.
Researchers found that standard DNA testing does not detect NUT carcinoma fusion genes in over 75% of patients. Additional tests like NUT immunohistochemistry and RNA fusion testing can reliably identify gene fusions, leading to more accurate diagnoses and potentially life-saving treatments.
A combination of two approved cancer medications may slow or reverse Alzheimer's symptoms by reversing gene expression changes in neurons and brain cells. Researchers analyzed public data from deceased donors and found a link between these drugs and reduced risk of developing the disease.
Researchers from Memorial Sloan Kettering Cancer Center developed a new approach to induce mutations in resistant cancer cells, making them sensitive to immunotherapy. The study showed positive outcomes in patients over 90 with lung cancer who underwent surgery.
A multidisciplinary guideline panel has determined that guided-bronchoscopy sampling provides tissue of comparable adequacy to percutaneous biopsy for comprehensive biomarker testing, while delivering a superior safety profile. Modern navigational bronchoscopy offers a safer path to molecular insights in lung cancer care.
Researchers at the University of Würzburg are developing a new therapy for KEAP1-mutated lung cancer using a sulfite inhibitor to block tumor cell growth. The team has identified a first-of-its-kind compound, SulfExstatin-1, which accumulates toxic sulfite in cancer cells, initiating their death.
Researchers at Mass General Brigham found that targeted radiation was successful in treating patients with brain metastases, resulting in a lower neurological death rate and reduced need for subsequent whole brain radiation. This study supports personalized treatment approaches to maintain quality of life while managing brain metastases.
A recent analysis of 16 years of data on Japanese adults reveals a strong association between socioeconomic status and the incidence of five common cancers. Communities with low employment rates or low incomes show higher cancer rates compared to those with higher socioeconomic status.
A new multi-institutional clinical trial will test zipalertinib, an investigational drug targeting specific EGFR mutations in early-stage non-small cell lung cancer. The goal is to prevent recurrence and improve long-term outcomes for patients with limited treatment options.
Researchers at Keck Medicine of USC found that high doses of corticosteroids can limit the effectiveness of immunotherapies in treating non-small cell lung cancer. Corticosteroids, commonly prescribed for symptom management, were shown to stop T-cells from maturing, reducing their ability to attack cancer cells.
A new study reveals that air pollution contributes to the development of lung cancer in people with no or hardly any history of smoking. The study found a strong association between air pollution and genetic mutations in lung tumors, particularly driver mutations that promote cancer development.
A whole-genome sequencing study found fine-particulate air pollution to cause more cancer-related changes than secondhand smoke. Researchers analyzed lung tumors from 871 never-smoker patients across 28 geographic locations worldwide and linked air pollution exposure to increased genomic changes.
Residential segregation contributes to lung cancer development in African Americans, highlighting the need for policymakers to address disparities. Structural racism in neighborhoods affects health outcomes, emphasizing the importance of reducing racial gaps in healthcare.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
A new study found diverse genetic patterns and treatment gaps in HER2-mutated non-small cell lung cancer (NSCLC) in Northeastern Brazil. The research highlights the importance of comprehensive molecular profiling and expanded access to targeted therapies for underrepresented populations.
A new dual-phase CT AI tool, NeoPred, combines pre-treatment and pre-surgery scans with clinical data to predict major pathological response in NSCLC patients. The model achieved high accuracy rates, including AUCs of 0.772-0.787, outperforming surgeons and improving diagnostic accuracy.
A study of 95 patients found that wrapping autologous tissue materials around anastomoses after airway reconstruction significantly reduced short-term postoperative complications. This technique may offer a positive effect on the prognosis of patients undergoing complex tracheobronchial resection and reconstruction.
Researchers found that lung cancer patients with both high levels of depression and inflammation at diagnosis had increasing depressive symptoms over the next eight months. These patients showed no changes in depression when only having high levels of depression or only high levels of inflammation, or neither. The study suggests an add...
A retrospective study found ESL to be a safe and viable alternative to pneumonectomy for selected patients with centrally located NSCLC. ESL offered better event-free survival compared to pneumonectomy.
A study of 203 patients shows that electromagnetic navigation bronchoscopy (ENBDM) is a safer and faster alternative to CT-guided localization for preoperative treatment of multiple pulmonary nodules in the same lung. ENBDM achieved comparable accuracy with lower complication rates, making it an optimal strategy.
The addition of perioperative toripalimab to platinum-based chemotherapy has demonstrated significant improvements in disease-related outcomes, including event-free survival and major pathologic response rates. However, this is associated with a small increase in grade 3–5 toxicities and immune-related adverse events.
Researchers developed a tool to monitor treatment response in patients with solid tumours using circulating tumour DNA analysis, anticipating clinical relapses up to 68 months before symptoms become apparent. The technology is minimally invasive and can be tailored to each tumour type, reducing unnecessary treatments and costs.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers found that cigarette smoke and reduced DNA repair capacity combine to increase cancer risk, with normal lung cells showing extensive damage after smoke exposure. The study's findings support a 'double hit' model, highlighting the critical role of XPC protein in preventing DNA damage.
A revolutionary AI model has been developed to diagnose lung cancer without relying on costly GPU servers or massive datasets. The ultra-lightweight model achieved a discrimination performance corresponding to an AUC value of 0.92, outperforming state-of-the-art large-scale AI systems.
The S2302 Pragmatica-Lung trial found that the investigational combination of ramucirumab and pembrolizumab did not extend overall survival compared to standard-of-care treatments. The study enrolled a highly representative population of patients, establishing it as a paradigm-shifting model for large randomized studies.
DB-1310, a HER3-targeted antibody-drug conjugate, has shown real potential as a new treatment option for patients with advanced solid tumors that have progressed after standard therapies. In an international clinical trial, DB-1310 demonstrated significant tumor shrinkage and delayed cancer growth in 44% of EGFR-mutant NSCLC patients.
Research reveals NADK tetramer defective mutants enhance tumor progression and chemotherapy resistance by regulating enzyme activity. Mutations impacting tetramer formation suppress activity, while others promote cancer cell growth and sensitivity to chemotherapy.
Researchers identified a new biomarker, TTF-1, that predicts survival outcomes for patients with advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib. Patients with low TTF-1 levels responded poorly to sotorasib, while those with high TTF-1 levels showed improved outcomes.
A new study has launched a novel blood test to identify people of Asian and Hispanic/Latinx descent who are at high risk of lung cancer but have never used tobacco. The trial aims to evaluate the feasibility of screening these individuals for free using CT scans, with the goal of detecting lung cancer at an early stage.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.